Mitral valve replacement and repair represent a rapidly evolving field in interventional cardiology, building on established experience with transcatheter aortic valve interventions. This comprehensive domain encompasses diverse innovative techniques and devices, with certain mitral repair solutions achieving widespread clinical adoption. Mastery of this complex specialty requires proficiency across multiple disciplines, including advanced imaging modalities such as echocardiography, vascular access strategies, emerging device technologies, pharmacological support, hemorrhage risk assessment, and sophisticated patient selection criteria. EuroIntervention serves as a leading reference journal dedicated to advancing knowledge in coronary, valvular, and structural interventions, providing clinicians with essential insights into the latest research and clinical developments shaping modern interventional practice.

The Mosaic Neo™ mitral bioprosthesis represents a next-generation native porcine valve designed for mitral valve replacement by Medtronic. Its innovative atrialized design reduces stent post protrusion by up to 23% compared to the legacy Mosaic™ valve, while strategically positioned cuff markings optimize leaflet orientation to preserve left ventricular outflow tract clearance. The wider interstrut distance at the anterior annulus minimizes obstruction risk. Long-term clinical evidence demonstrates superior durability compared to bovine pericardial alternatives, with significantly extended intervals before reoperation for structural valve deterioration. The platform incorporates enhanced procedural features including intuitive cuff markings, pre-attached barrel sizers, and a quick-detach handle system designed to streamline implantation and improve surgical workflow efficiency.

Effective management of primary mitral regurgitation demands a comprehensive lifetime strategy integrating both surgical and transcatheter interventions. Contemporary practice emphasizes early intervention timing, repair durability, and strategic planning for potential future reinterventions. A multidisciplinary Heart Team approach is essential to design the initial procedure while preserving therapeutic flexibility across the patient's lifespan. The recently updated 2025 ESC/EACTS Valvular Heart Disease Guidelines provide refined indications for early surgery, improved patient selection criteria for transcatheter edge-to-edge repair, and expanded recommendations for prosthetic valve failure management. This framework enables clinicians to pursue durable surgical repair as the primary goal while maintaining accessible options for subsequent interventions, ensuring optimal long-term outcomes for patients requiring mitral valve intervention.

Transcatheter tricuspid valve interventions have evolved significantly through early clinical experience and iterative refinement. The Cardioband system's early adoption highlighted critical challenges in direct annuloplasty, including technical complexity, imaging limitations, and anchor instability despite sound physiological principles. These lessons revealed that annular dilatation remains the primary driver of secondary tricuspid regurgitation, emphasizing the continued importance of annuloplasty as a therapeutic strategy. Future device development must address engineering constraints and workflow optimization to achieve reproducible, scalable interventions that build upon the foundation established by pioneering experiences.

Boston Scientific seeks an experienced Interventional Cardiologist for the Global Medical Director position in Maple Grove, Minnesota. This hybrid role offers physician leadership within the Global Cardiology Group, requiring presence in the office at least three times weekly. The successful candidate will provide medical expertise and strategic guidance across coronary, structural heart, and renal denervation technologies, serving as the clinical voice throughout the product lifecycle. Responsibilities include partnering with Clinical, R&D, Quality, Regulatory Affairs, and Commercial teams to advance clinical evidence generation, product development, and medical strategy. The position offers an opportunity to influence cardiovascular care advancement while supporting patient safety and therapeutic innovation globally. Boston Scientific provides comprehensive professional development, diverse team environments, and recognized workplace culture benefits. No visa sponsorship is available.

Integrating human factors into post-market surveillance represents a critical evolution in medical device safety management. While premarket usability studies establish baseline performance, real-world use generates insights that traditional surveillance mechanisms often miss. Both EU MDR and FDA regulations increasingly emphasize continuous demonstration of device usability and safety throughout product lifecycles. By incorporating human factors methodology into post-market surveillance activities, manufacturers can identify user interaction issues, understand root causes of problems, and proactively address safety risks. This integration strengthens regulatory compliance, reduces costly recalls and corrective actions, and ultimately delivers safer, more user-friendly devices that better serve clinical needs in practice.  

The Corindus CorPath robotic system represents an advanced technological solution for percutaneous coronary intervention procedures within cardiac catheterization laboratories. This robotic platform enhances precision and control during complex coronary interventions, enabling clinicians to perform minimally invasive cardiac procedures with improved accuracy. The CorPath system demonstrates the growing integration of robotics and automation in interventional cardiology, potentially reducing procedural complications and improving patient outcomes. This innovation reflects the healthcare industry's commitment to leveraging cutting-edge technology to advance cardiac care capabilities and operational efficiency in modern cath labs.

The European Union Medical Device Regulation (MDR), implemented in May 2021, represents a significant overhaul of Europe's medical device regulatory framework, replacing the previous Medical Device Directive. This comprehensive update strengthens patient safety and product transparency by introducing stricter manufacturer requirements, enhanced clinical evidence standards, and rigorous post-market surveillance protocols. The MDR expands device definitions and reinforces clinical oversight to keep pace with technological advancements. These changes substantially impact manufacturers, healthcare professionals, and patients across Europe, requiring stakeholders to adapt their compliance strategies and operational procedures to meet the heightened safety and effectiveness standards now mandated by the regulatory framework.

# Professional Summary Recent advances in cardiovascular implant technology have significantly enhanced device longevity and clinical outcomes. Contemporary developments focus on sophisticated anti-mineralization processes that specifically target calcium-binding phospholipids and aldehyde residues, substantially improving valve durability and performance. These innovations represent a critical evolution in implant design, addressing historical limitations that compromised device longevity. The integration of proprietary bioengineering techniques has enabled manufacturers to develop more resilient materials resistant to calcification and tissue degradation. These improvements translate to extended implant lifespan, reduced revision surgeries, and improved patient outcomes. The field continues advancing through refined material science approaches and targeted chemical modifications, positioning cardiovascular implants as increasingly reliable long-term solutions for patients requiring cardiac intervention.

This prospective, multicenter, observational cohort study aims to establish a post-market registry framework to evaluate the real-world clinical applicability, long-term safety, and effectiveness of innovative heart valve devices in China.

Transcatheter tricuspid valve interventions represent a rapidly evolving field shaped by early clinical experiences and iterative innovation. The formative period of development involved exploratory approaches derived from mitral valve techniques, which yielded important lessons from both successes and setbacks. Early obstacles, such as technical complexity and imaging limitations encountered with direct annuloplasty approaches like the Cardioband system, redirected research efforts and deepened understanding of tricuspid anatomy and physiology. These foundational experiences have informed current therapeutic strategies and established parameters for future innovations. The article examines what has failed, what has proven effective, and emerging approaches in transcatheter tricuspid valve intervention, providing valuable insights for the cardiothoracic surgery community navigating this dynamic treatment landscape.

Robotic-assisted percutaneous coronary intervention represents an emerging advancement in coronary revascularization techniques. This article examines the current evidence and future potential of robotic systems in PCI procedures, comparing them to conventional manual techniques. While manual PCI remains the standard approach for treating coronary artery disease across acute and chronic presentations, robotic-assisted methods offer potential advantages including reduced operator radiation exposure and improved procedural precision. The review discusses applications in various clinical scenarios, from chronic coronary syndromes to acute myocardial infarctions, while emphasizing the importance of individualized patient management strategies and the need for continued investigation into when robotic assistance may provide clinical benefits.

The guidelines are introduced by NMPA Center of Medical Device Evaluation (CMDE). It is not legally binding but highly recommended by regulatory authorities. The revision plan will not only impact the new product registration but also renewals and modifications. It involves type testing, clinical, registration review guidelines, technical guidelines, e.g., Real World Study design, and documentation guidelines, e.g., Indication for Use (IFU) writing. NMPA issues new or updated guidelines throughout the year. Given their importance in understanding what the NMPA reviewers are looking for, it is essential that manufacturers keep up to date with the guidelines that are latest to their specific products. One source to get updates on these guidelines is through our complimentary monthly news roundup that you can opt in from our website www.ChinaMedDevice.com

TruLeaf Medical, Ltd, a fully-owned subsidiary of Allmed Solutions (TASE: ALMD), a clinical-stage medical device company specializing in transcatheter structural heart innovations, is pleased to announce the successful completion of the full two-stage percutaneous heart valve implantation procedure in two additional high-risk patients suffering from severe, refractory heart failure due to leaky tricuspid valve (TR). The first stage of the docking device implantation was performed 3 months ago. In recent days, the second stage of fully percutaneous transcatheter heart valve implantation within the TruLeaf RoseDocdocking station, was successfully performed at a leading medical center in India under a compassionate-use framework. This milestone achievement, conducted in collaboration with a prominent international medical device partner, further validates the clinical utility of TruLeaf Medical RoseDoc  TTVR system for high-risk, no-other-option patients suffering from severe refractory heart failure due to severe TR.

A new multicenter study published in The Annals of Thoracic Surgery finds that reoperative surgical mitral valve replacement (rSMVR) is associated with significantly better long-term survival compared to transcatheter mitral valve-in-valve (mViV) procedures in patients with failing bioprosthetic mitral valves. While both approaches demonstrated similar safety and procedural success at 30 days, key differences emerged over time, particularly beyond the first year.

Recent clinical trials presented at ACC.26 demonstrate promising advances in structural cardiac interventions. The PROTECT H2H trial evaluated embolic protection devices during transcatheter aortic valve implantation, comparing the Emboliner device with the standard Sentinel device across 522 patients. Despite periprocedural stroke occurring in only 2-4% of TAVI cases, it remains a significant concern. The trial assessed 30-day major adverse cardiovascular and cerebrovascular events as its primary endpoint. Additional late-breaking trials included PRO-TAVI, which compared routine percutaneous coronary intervention strategies with deferred approaches in TAVI patients, and SURViV, examining redo surgery versus transcatheter valve-in-valve procedures for mitral bioprosthetic dysfunction. These trials collectively provide clinicians with viable alternative options for managing complex structural cardiac conditions.

A multicenter study published in The Annals of Thoracic Surgery demonstrates that reoperative surgical mitral valve replacement provides superior long-term survival outcomes compared to transcatheter mitral valve-in-valve procedures for patients with failing bioprosthetic mitral valves. Analyzing 229 patients from two high-volume centers between 2004 and 2023, researchers found comparable safety profiles and procedural success within 30 days. However, significant divergence emerged beyond one year, with surgical patients achieving substantially lower five-year mortality rates of 20.3% versus 40.9% for transcatheter procedures, alongside superior valve durability and lower gradients. While transcatheter approaches offered shorter hospital stays and fewer early complications, the study emphasizes that surgical intervention delivers greater long-term benefits in appropriately selected patients. These findings support multidisciplinary heart team decision-making, balancing short-term advantages of transcatheter procedures against the enduring survival benefits of surgical replacement, particularly for low-risk patients with extended life expectancy.

Although mViV demonstrated comparable 30-day MVARC outcomes, rSMVR was associated with superior long-term survival and hemodynamic durability among patients deemed appropriate surgical candidates by a multidisciplinary heart team. Treatment decisions should balance short-term risk with long-term outcomes.

Researchers have demonstrated significant sustained clinical benefits from a novel minimally invasive treatment for mitral regurgitation patients who lack conventional surgical options. The AltaValve Early Feasibility Study, presented at the 2026 SCAI Scientific Sessions in Montreal, shows one-year improvement in patients treated with atrial fixation Transcatheter Mitral Valve Replacement. Mitral regurgitation, affecting over 175 million people globally, occurs when the mitral valve fails to close properly, allowing blood to leak backward. This emerging technique offers hope for elderly patients and those with anatomical constraints unsuitable for traditional interventions by placing a prosthetic valve above the diseased valve, reducing left ventricular outflow tract obstruction risks.

Recent clinical evidence demonstrates that transcatheter mitral valve-in-valve procedures offer superior outcomes compared to traditional redo surgery in patients with failed mitral bioprostheses. This minimally invasive approach provides significant advantages in terms of reduced procedural risk, shorter recovery times, and improved patient safety profiles. The transcatheter technique represents an important advancement in interventional cardiology, offering a viable alternative for high-risk surgical candidates requiring mitral valve replacement. These findings suggest a paradigm shift in treatment strategies for managing bioprosthetic valve failure, potentially expanding treatment options and improving clinical outcomes for affected patients.